<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Abuse Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Abuse Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance abuse treatment</journal-title></journal-title-group><issn pub-type="ppub">0740-5472</issn><issn pub-type="epub">1873-6483</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10012431</article-id><article-id pub-id-type="pmcid-ver">PMC10012431.1</article-id><article-id pub-id-type="pmcaid">10012431</article-id><article-id pub-id-type="pmcaiid">10012431</article-id><article-id pub-id-type="manuscript-id">NIHMS1865111</article-id><article-id pub-id-type="pmid">35773113</article-id><article-id pub-id-type="doi">10.1016/j.jsat.2022.108830</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1865111</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1865111</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bunting</surname><given-names initials="AM">Amanda M.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krawczyk</surname><given-names initials="N">Noa</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Choo</surname><given-names initials="TH">Tse-Hwei</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pavlicova</surname><given-names initials="M">Martina</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McNeely</surname><given-names initials="J">Jennifer</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tofighi</surname><given-names initials="B">Babak</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rotrosen</surname><given-names initials="J">John</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nunes</surname><given-names initials="E">Edward</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JD">Joshua D.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A5" ref-type="aff">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Population Health, NYU School of Medicine, New York, NY</aff><aff id="A2"><label>2</label>Department of Biostatistics, Mailman School of Public Health, Columbia University</aff><aff id="A3"><label>3</label>Department of Psychiatry, Columbia University</aff><aff id="A4"><label>4</label>Department of Psychiatry, NYU School of Medicine, New York, NY</aff><aff id="A5"><label>5.</label>Division of General Internal Medicine and Clinical Innovation, NYU School of Medicine, New York, NY</aff><author-notes><corresp id="CR1">Corresponding author: Amanda M. Bunting, <email>amanda.bunting@nyulangone.org</email>, 180 Madison Ave, New York, NY 10016</corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>22</day><month>6</month><year>2022</year></pub-date><volume>143</volume><issue-id pub-id-type="pmc-issue-id">431171</issue-id><fpage>108830</fpage><lpage>108830</lpage><pub-history><event event-type="nihms-submitted"><date><day>15</day><month>02</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 05:25:25.783"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1865111.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P1">Polysubstance use may complicate treatment outcomes for individuals who use opioids. This research aimed to examine the prevalence of polysubstance use in an opioid use disorder treatment trial population and polysubstance use&#8217;s association with opioid relapse and craving.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">This study is a secondary data analysis of individuals with opioid use disorder who received at least one dose of medication (n=474) as part of a 24-week, multi-site, open label, randomized Clinical Trials Network study (CTN0051, X:BOT) comparing the effectiveness of extended-release naltrexone versus buprenorphine. Models examined pretreatment polysubstance use and polysubstance use during the initial 4 weeks of treatment on outcomes of relapse by week 24 of the treatment trial and opioid craving.</p></sec><sec id="S3"><title>Results:</title><p id="P3">Polysubstance use was generally not associated with treatment outcomes of opioid relapse and craving. Proportion of days of pretreatment sedative use was associated with increased likelihood of opioid relapse (OR: 1.01, 95% CI: 1.00&#8211;1.02). Proportion of days of cocaine use during the initial 4 weeks of treatment was associated with increased likelihood of opioid relapse (OR: 1.05, 95% CI: 1.01&#8211;1.09) but this effect was no longer significant once the potential of confounding by opioid use was considered. Sedative use during initial 4 weeks of treatment was associated with increased opioid craving (b: 0.77, 95% CI: 0.01&#8211;1.52). The study found no other significant relationships.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">In the current study population, polysubstance use was only marginally associated with 24-week treatment outcomes.</p></sec></abstract><kwd-group><kwd>Polysubstance use</kwd><kwd>Opioid use disorder</kwd><kwd>Buprenorphine</kwd><kwd>Naltrexone</kwd><kwd>Treatment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>